O	0	10	Appearance	Appearance	NN	B-NP
O	11	13	of	of	IN	B-PP
B-Cancer	14	22	tumorous	tumorous	JJ	B-NP
O	23	33	phenotypes	phenotype	NNS	I-NP
O	34	36	in	in	IN	B-PP
O	37	45	goldfish	goldfish	NN	B-NP
B-Cell	46	59	erythrophores	erythrophore	NNS	I-NP
O	60	71	transfected	transfecte	VBN	B-VP
O	72	76	with	with	IN	B-PP
O	77	80	ras	ras	NN	B-NP
O	80	81	,	,	,	O
O	82	85	src	src	NN	B-NP
O	85	86	,	,	,	O
O	87	90	and	and	CC	O
O	91	94	myc	myc	NN	B-NP
O	95	104	oncogenes	oncogene	NNS	I-NP
O	105	108	and	and	CC	O
O	109	120	spontaneous	spontaneous	JJ	B-NP
O	121	136	differentiation	differentiation	NN	I-NP
O	137	139	of	of	IN	B-PP
O	140	143	the	the	DT	B-NP
B-Cell	144	157	transformants	transformant	NNS	I-NP
O	158	160	in	in	FW	B-ADVP
O	161	166	vitro	vitro	FW	I-ADVP
O	166	167	.	.	.	O

O	169	173	When	When	WRB	B-ADVP
O	174	182	goldfish	goldfish	NN	B-NP
B-Cell	183	196	erythrophores	erythrophore	NNS	I-NP
O	197	205	isolated	isolate	VBN	B-VP
O	206	210	from	from	IN	B-PP
O	211	214	the	the	DT	B-NP
B-Organ	215	219	skin	skin	NN	I-NP
O	220	222	by	by	IN	B-PP
B-Tissue	223	229	tissue	tissue	NN	B-NP
O	230	239	digestion	digestion	NN	I-NP
O	240	243	and	and	CC	I-NP
O	244	258	centrifugation	centrifugation	NN	I-NP
O	259	261	in	in	IN	B-PP
O	262	263	a	a	DT	B-NP
O	264	271	Percoll	Percoll	NN	I-NP
O	272	279	density	density	NN	I-NP
O	280	288	gradient	gradient	NN	I-NP
O	289	293	were	be	VBD	B-VP
O	294	305	transfected	transfecte	VBN	I-VP
O	306	308	in	in	IN	B-PP
O	309	310	a	a	DT	B-NP
B-Cell	311	320	monolayer	monolayer	NN	I-NP
I-Cell	320	321	-	-	HYPH	O
I-Cell	321	328	culture	culture	NN	B-NP
O	329	333	with	with	IN	B-PP
O	334	335	v	v	NN	B-NP
O	335	336	-	-	HYPH	B-NP
O	336	338	Ha	Ha	NN	I-NP
O	338	339	-	-	HYPH	B-NP
O	339	342	ras	ras	NN	I-NP
O	343	345	or	or	CC	I-NP
O	346	347	v	v	NN	I-NP
O	347	348	-	-	HYPH	B-NP
O	348	351	src	src	NN	I-NP
O	352	360	oncogene	oncogene	NN	I-NP
O	361	367	either	either	CC	O
O	368	374	singly	singly	RB	B-ADVP
O	375	377	or	or	CC	O
O	378	380	in	in	IN	B-PP
O	381	392	combination	combination	NN	B-NP
O	393	397	with	with	IN	B-PP
O	398	399	v	v	NN	B-NP
O	399	400	-	-	HYPH	I-NP
O	400	403	myc	myc	NN	I-NP
O	404	406	by	by	IN	B-PP
O	407	412	means	mean	NNS	B-NP
O	413	415	of	of	IN	B-PP
O	416	423	calcium	calcium	NN	B-NP
O	424	433	phosphate	phosphate	NN	I-NP
O	433	434	-	-	HYPH	B-NP
O	434	437	DNA	DNA	NN	I-NP
O	438	440	co	co	AFX	O
O	440	441	-	-	HYPH	O
O	441	454	precipitation	precipitation	NN	B-NP
O	454	455	,	,	,	O
O	456	461	there	there	EX	B-NP
O	462	470	appeared	appear	VBD	B-VP
O	471	472	a	a	DT	B-NP
O	473	480	certain	certain	JJ	I-NP
O	481	487	number	number	NN	I-NP
O	488	490	of	of	IN	B-PP
B-Cell	491	504	transformants	transformant	NNS	B-NP
O	505	516	manifesting	manifest	VBG	B-VP
O	517	518	a	a	DT	B-NP
B-Cell	519	532	chromatoblast	chromatoblast	NN	I-NP
O	532	533	-	-	HYPH	B-NP
O	533	537	like	like	JJ	I-NP
O	538	545	profile	profile	NN	I-NP
O	546	549	and	and	CC	I-NP
B-Cancer	550	558	tumorous	tumorous	JJ	I-NP
O	559	569	phenotypes	phenotype	NNS	I-NP
O	570	572	as	as	IN	B-SBAR
O	573	577	seen	see	VBN	B-VP
O	578	580	in	in	IN	B-PP
O	581	584	the	the	DT	B-NP
O	585	595	capability	capability	NN	I-NP
O	596	599	for	for	IN	B-PP
O	600	609	unlimited	unlimited	JJ	B-NP
O	610	616	growth	growth	NN	I-NP
O	616	617	,	,	,	O
O	618	621	and	and	CC	O
O	622	628	piling	piling	NN	B-NP
O	628	629	-	-	HYPH	B-VP
O	629	631	up	up	RP	B-PRT
O	632	634	in	in	IN	B-PP
O	635	636	a	a	DT	B-NP
B-Cell	637	646	monolayer	monolayer	NN	I-NP
I-Cell	646	647	-	-	HYPH	B-NP
I-Cell	647	654	culture	culture	NN	I-NP
O	655	657	or	or	CC	I-NP
B-Cell	658	664	colony	colony	NN	I-NP
O	665	674	formation	formation	NN	I-NP
O	675	677	in	in	IN	B-PP
O	678	682	semi	semi	AFX	B-NP
O	682	683	-	-	HYPH	I-NP
O	683	688	solid	solid	JJ	I-NP
O	689	693	soft	soft	JJ	I-NP
O	694	698	agar	agar	NN	I-NP
O	698	699	.	.	.	O

O	700	705	After	After	IN	B-PP
O	706	716	successive	successive	JJ	B-NP
O	717	723	growth	growth	NN	I-NP
O	724	726	in	in	FW	B-ADVP
O	727	732	vitro	vitro	FW	I-ADVP
O	733	736	for	for	IN	B-PP
O	737	743	longer	long	JJR	B-NP
O	744	748	than	than	IN	I-NP
O	749	752	one	one	CD	I-NP
O	753	758	month	month	NN	I-NP
O	759	764	which	which	WDT	B-NP
O	765	768	was	be	VBD	B-VP
O	769	777	scarcely	scarcely	RB	I-VP
O	778	786	observed	observe	VBN	I-VP
O	787	791	with	with	IN	B-PP
O	792	795	the	the	DT	B-NP
B-Cell	796	809	erythrophores	erythrophore	NNS	I-NP
O	809	810	,	,	,	O
O	811	814	the	the	DT	B-NP
O	815	819	vast	vast	JJ	I-NP
O	820	828	majority	majority	NN	I-NP
O	829	831	of	of	IN	B-PP
O	832	836	such	such	JJ	B-NP
B-Cell	837	850	transformants	transformant	NNS	I-NP
O	851	856	began	begin	VBD	B-VP
O	857	859	to	to	TO	I-VP
O	860	873	differentiate	differentiate	VB	I-VP
O	874	878	into	into	IN	B-PP
B-Cell	879	892	erythrophores	erythrophore	NNS	B-NP
O	893	896	and	and	CC	O
O	897	903	ceased	cease	VBD	B-VP
O	904	917	proliferation	proliferation	NN	B-NP
O	918	931	spontaneously	spontaneously	RB	B-ADVP
O	931	932	.	.	.	O

O	933	936	The	The	DT	B-NP
O	937	942	onset	onset	NN	I-NP
O	943	945	of	of	IN	B-PP
O	946	951	their	their	PRP$	B-NP
O	952	967	differentiation	differentiation	NN	I-NP
O	968	971	was	be	VBD	B-VP
O	972	983	ascertained	ascertain	VBN	I-VP
O	984	986	by	by	IN	B-PP
O	987	990	the	the	DT	B-NP
O	991	1001	deposition	deposition	NN	I-NP
O	1002	1004	of	of	IN	B-PP
O	1005	1011	marker	marker	NN	B-NP
O	1012	1021	pteridine	pteridine	NN	I-NP
O	1022	1030	pigments	pigment	NNS	I-NP
O	1030	1031	.	.	.	O

O	1032	1036	None	None	NN	B-NP
O	1037	1039	of	of	IN	B-PP
O	1040	1043	the	the	DT	B-NP
B-Cell	1044	1057	transformants	transformant	NNS	I-NP
O	1058	1072	differentiated	differentiate	VBN	B-VP
O	1073	1077	into	into	IN	B-PP
B-Cell	1078	1090	melanophores	melanophore	NNS	B-NP
O	1091	1093	or	or	CC	I-NP
B-Cell	1094	1105	iridophores	iridophore	NNS	I-NP
O	1106	1108	or	or	CC	O
O	1109	1114	other	other	JJ	B-NP
B-Cell	1115	1121	neural	neural	JJ	I-NP
I-Cell	1122	1127	crest	crest	NN	I-NP
O	1128	1139	derivatives	derivative	NNS	I-NP
O	1140	1142	as	as	IN	B-SBAR
O	1143	1147	seen	see	VBN	B-VP
O	1148	1150	in	in	IN	B-PP
O	1151	1159	goldfish	goldfish	NN	B-NP
B-Cell	1160	1174	erythrophoroma	erythrophoroma	NN	I-NP
I-Cell	1175	1180	cells	cell	NNS	I-NP
O	1180	1181	.	.	.	O

O	1182	1188	Little	Little	JJ	B-NP
O	1189	1199	difference	difference	NN	I-NP
O	1200	1203	was	be	VBD	B-VP
O	1204	1212	observed	observe	VBN	I-VP
O	1213	1215	in	in	IN	B-PP
O	1216	1221	their	their	PRP$	B-NP
O	1222	1234	transforming	transform	VBG	I-NP
O	1235	1245	efficiency	efficiency	NN	I-NP
O	1246	1247	(	(	(	O
O	1247	1248	0	0	CD	B-NP
O	1248	1249	.	.	.	O
O	1249	1250	2	2	CD	B-NP
O	1250	1251	-	-	HYPH	I-NP
O	1251	1252	0	0	CD	I-NP
O	1252	1253	.	.	.	O
O	1253	1254	3	3	CD	B-NP
B-Cell	1255	1268	transformants	transformant	NNS	I-NP
O	1268	1269	/	/	SYM	B-NP
O	1269	1279	micrograms	microgram	NNS	I-NP
O	1280	1283	DNA	DNA	NN	I-NP
O	1283	1284	)	)	)	O
O	1285	1292	between	between	IN	B-PP
O	1293	1296	the	the	DT	B-NP
O	1297	1309	combinations	combination	NNS	I-NP
O	1310	1312	of	of	IN	B-PP
O	1313	1322	oncogenes	oncogene	NNS	B-NP
O	1323	1330	applied	apply	VBD	B-VP
O	1331	1334	but	but	CC	O
O	1335	1336	a	a	DT	B-NP
O	1337	1345	tendency	tendency	NN	I-NP
O	1346	1349	was	be	VBD	B-VP
O	1350	1355	noted	note	VBN	I-VP
O	1356	1360	that	that	IN	B-SBAR
B-Cell	1361	1366	cells	cell	NNS	B-NP
O	1367	1378	transfected	transfecte	VBN	B-VP
O	1379	1383	with	with	IN	B-PP
O	1384	1387	ras	ras	NN	B-NP
O	1388	1390	or	or	CC	I-NP
O	1391	1394	src	src	NN	I-NP
O	1395	1397	in	in	IN	B-PP
O	1398	1409	combination	combination	NN	B-NP
O	1410	1414	with	with	IN	B-PP
O	1415	1418	myc	myc	NN	B-NP
O	1419	1428	developed	develop	VBD	B-VP
O	1429	1432	the	the	DT	B-NP
O	1433	1441	capacity	capacity	NN	I-NP
O	1442	1444	to	to	TO	B-VP
O	1445	1449	grow	grow	VB	I-VP
O	1450	1453	for	for	IN	B-PP
O	1454	1455	a	a	DT	B-NP
O	1456	1462	longer	long	JJR	I-NP
O	1463	1469	period	period	NN	I-NP
O	1470	1473	and	and	CC	O
O	1474	1488	differentiated	differentiate	VBD	B-VP
O	1489	1491	at	at	IN	B-PP
O	1492	1493	a	a	DT	B-NP
O	1494	1499	later	later	JJ	I-NP
O	1500	1505	stage	stage	NN	I-NP
O	1506	1510	than	than	IN	B-PP
O	1511	1516	those	those	DT	B-NP
O	1517	1528	transfected	transfecte	VBN	B-VP
O	1529	1535	solely	solely	RB	B-ADVP
O	1536	1540	with	with	IN	B-PP
O	1541	1544	ras	ras	NN	B-NP
O	1545	1547	or	or	CC	I-NP
O	1548	1551	src	src	NN	I-NP
O	1551	1552	.	.	.	O

O	1553	1556	One	One	CD	B-NP
B-Cell	1557	1561	cell	cell	NN	I-NP
I-Cell	1562	1566	line	line	NN	I-NP
O	1567	1568	(	(	(	O
B-Cell	1568	1571	ESM	ESM	NN	B-NP
I-Cell	1571	1572	-	-	HYPH	B-NP
I-Cell	1572	1573	1	1	CD	I-NP
O	1573	1574	)	)	)	O
O	1575	1582	derived	derive	VBN	B-VP
O	1583	1587	from	from	IN	B-PP
O	1588	1591	the	the	DT	B-NP
B-Cell	1592	1605	erythrophores	erythrophore	NNS	I-NP
O	1606	1617	transfected	transfecte	VBN	B-VP
O	1618	1622	with	with	IN	B-PP
O	1623	1626	src	src	NN	B-NP
O	1626	1627	/	/	SYM	B-NP
O	1627	1630	myc	myc	NN	I-NP
O	1631	1635	grew	grow	VBD	B-VP
O	1636	1648	successively	successively	RB	B-NP
O	1649	1653	over	over	IN	I-NP
O	1654	1658	nine	nine	CD	I-NP
O	1659	1665	months	month	NNS	I-NP
O	1665	1666	,	,	,	O
O	1667	1677	indicating	indicate	VBG	B-VP
O	1678	1681	its	its	PRP$	B-NP
O	1682	1693	acquisition	acquisition	NN	I-NP
O	1694	1696	of	of	IN	B-PP
O	1697	1708	immortality	immortality	NN	B-NP
O	1708	1709	.	.	.	O

O	1710	1713	The	The	DT	B-NP
O	1714	1724	expression	expression	NN	I-NP
O	1725	1727	of	of	IN	B-PP
O	1728	1731	the	the	DT	B-NP
O	1732	1743	transfected	transfecte	VBN	I-NP
O	1744	1753	oncogenes	oncogene	NNS	I-NP
O	1754	1756	in	in	IN	B-PP
O	1757	1761	this	this	DT	B-NP
B-Cell	1762	1766	cell	cell	NN	I-NP
I-Cell	1767	1771	line	line	NN	I-NP
O	1772	1775	was	be	VBD	B-VP
O	1776	1784	examined	examine	VBN	I-VP
O	1785	1787	in	in	IN	B-PP
O	1788	1798	comparison	comparison	NN	B-NP
O	1799	1803	with	with	IN	B-PP
O	1804	1807	the	the	DT	B-NP
B-Cell	1808	1822	erythrophoroma	erythrophoroma	NN	I-NP
I-Cell	1823	1828	cells	cell	NNS	I-NP
O	1829	1831	by	by	IN	B-PP
O	1832	1839	Western	Western	JJ	B-NP
O	1840	1843	and	and	CC	I-NP
O	1844	1852	Northern	Northern	JJ	I-NP
O	1853	1857	blot	blot	NN	I-NP
O	1858	1866	analyses	analysis	NNS	I-NP
O	1866	1867	.	.	.	O

